<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852928</url>
  </required_header>
  <id_info>
    <org_study_id>chILD-EU</org_study_id>
    <nct_id>NCT02852928</nct_id>
  </id_info>
  <brief_title>European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank</brief_title>
  <acronym>chILD-EU</acronym>
  <official_title>Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generation of a common European database and biobank Continous assessment and implementation
      of guidelines and treatment protocols Establishment of a large observational cohort of chILD
      patients Determination the value of outcomes used in child Assess treatment variations used,
      deliver data from defined protocols and linked outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective 1: Generation of a common European database and biobank. The existing national
      programmes to collect data on chILD in three countries (France, Germany, UK) will enable the
      consortium to swiftly adapt current frameworks to a functionally appropriate pan-European
      web-based database and biobank. Importantly, compatibility with ongoing United States chILD
      data base developments will be factored in.

      Objective 2: Continuous assessment and implementation of guidelines and treatment protocols.
      Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific
      diagnostic pathways, including detailed protocols for gathering clinical information, blood
      testing, imaging and pathology (&quot;Best Practice Checklist&quot;); (b) international panels of
      clinicians, geneticists, radiologists and pathologists who will review every diagnosis to
      quality control the data; and (c) detailed protocols for follow up to generate natural
      history data.

      Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide
      recruitment and interdisciplinary critical peer review of all diagnoses submitted from across
      Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis
      is possible, we will review the case periodically as new information becomes available.
      During the first year of the study, clinicians´ decisions according to local practice and
      outcomes will be independently monitored and assessed.

      Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize
      and clarify the relative weight of a large spectrum of single and composite clinical outcomes
      (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation
      exposure), lung function testing, histopathological categorization of lung biopsies, serum
      markers and genetic tests. Variability, reproducibility and the effects of training on
      reading images will be investigated.

      Objective 5: Assess treatment variations used, deliver data from defined protocols and linked
      outcomes. This project will analyse in detail treatment and outcomes within and between
      subjects using data collected. Analysis of the collected data will enable us to support the
      definition of trial protocols planned in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Included subjects with specific diagnosis</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survial</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <condition>Pulmonary Eosinophilia</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Child</condition>
  <eligibility>
    <study_pop>
      <textblock>
        400 prevalent patients with childhood interstitial lung disease (chILD) in Europe 100
        incident chILD cases per year
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all children with suspected or

          -  verified diagnosis of ILD or

          -  masquerading as ILD and

          -  those with rare localized parenchymal lung diseases

        Exclusion Criteria:

          -  other indication as inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universität München, Dr. von Haunersches Kinderspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Cunningham, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Griese, Prof.</last_name>
    <phone>+49/89/440057871</phone>
    <email>Matthias.Griese@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meike Hengst, Dr. med.</last_name>
    <phone>+49/89/440057878</phone>
    <email>Meike.Hengst@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université Pierre et Marie Curie</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annick Clement, Prof</last_name>
      <phone>+33-1 44 73 66 68</phone>
      <email>annick.clement@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Schwerk, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
      <email>schwerk.nicolaus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wetzke, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Snijders, Dr</last_name>
      <phone>+39 049 821 8015</phone>
      <email>deborah.snijders@sanita.padova.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <state>Sihhiye</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nural Kiper, Prof</last_name>
      <phone>+903123051224</phone>
      <email>nkiper@hacettepe.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Nagehan Emiralioglu, Dr.</last_name>
      <phone>+903123051334</phone>
      <email>nagehan.emiralioglu@hacettepe.edu.tr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Cuningham, Dr.</last_name>
      <phone>+441315360640</phone>
      <email>steve.cunningham@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Morag MaClean</last_name>
      <phone>+44131 537 3846 / 3878</phone>
      <email>chILD-UK@ed.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://childeu.net</url>
    <description>chILD-EU project website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>September 30, 2017</last_update_submitted>
  <last_update_submitted_qc>September 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ILD; chILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

